

## **Immunotherapy Part II References**

Special Guest: Matt McKenzie, PharmD, BCCCP

### **Guidelines**

Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2022 Apr;20(4):387-405. <https://pubmed.ncbi.nlm.nih.gov/35390769/>

Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. *J Clin Oncol*. 2021 Dec 10;39(35):3978-3992. <https://pubmed.ncbi.nlm.nih.gov/34724386/>

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. *J Clin Oncol*. 2021 Dec 20;39(36):4073-4126. <https://pubmed.ncbi.nlm.nih.gov/34724392/>

ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2022 Dec;33(12):1217-1238. <https://pubmed.ncbi.nlm.nih.gov/36270461/>

Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant*. 2019 Apr;25(4):625-638. <https://pubmed.ncbi.nlm.nih.gov/30592986/>

### **Review Articles**

Mucha SR, Rajendram P. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications. *Curr Oncol*. 2023 May 15;30(5):5003-5023. <https://pubmed.ncbi.nlm.nih.gov/37232836/>

Dushenkov A, Jungsuwadee P. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice. *J Oncol Pharm Pract*. 2019 Jul;25(5):1217-1225.

Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. *N Engl J Med*. 2018 Jan 11;378(2):158-168. <https://pubmed.ncbi.nlm.nih.gov/29320654/>

## **Articles Referenced**

Strati P, Jallouk A, Deng Q, et al. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. *Blood Adv*. 2023 Nov 14;7(21):6785-6789.

<https://pubmed.ncbi.nlm.nih.gov/37389847/>

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*. 2017 Dec 28;377(26):2531-

2544. <https://pubmed.ncbi.nlm.nih.gov/29226797/>

Gutierrez C, Brown ART, May HP, et al. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study. *Crit Care Med*. 2022 Jan 1;50(1):81-92.

<https://pubmed.ncbi.nlm.nih.gov/34259446/>

Gutierrez C, Brown ART, Herr MM, et al. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. *J Crit Care*. 2020 Aug;58:58-64.

<https://pubmed.ncbi.nlm.nih.gov/32361219/>

Saw JL, Sidiqi MH, Ruff M, et al. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). *Blood Cancer J*. 2022 Apr

13;12(4):62. <https://pubmed.ncbi.nlm.nih.gov/35418113/>

Constantinescu C, Moisoiu V, Tigu B, et al Outcomes of CAR-T Cell Therapy Recipients Admitted to the ICU: In Search for a Standard of Care-A Brief Overview and Meta-Analysis of Proportions. *J Clin Med*. 2023 Sep 21;12(18):6098. <https://pubmed.ncbi.nlm.nih.gov/37763039/>